New Delhi, Oct 28 (PTI) Drug firm Cipla on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).

"As part of the collaborative effort, Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA Ltd," Cipla said in a statement.

Also Read | Bank Jobs 2020-21: UCO Bank, IBPS, SBI and More, Check Out Vacancies, Official Websites and Important Dates to Apply at Various Banking Recruitment Exams.

ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers. The product will be marketed under the brand name ELIFast, it added.

Cipla's distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR to ensure equitable access, the statement said.

Also Read | How US is Voting in Presidential Election 2020: Early Voting, In-Person Voting, Mail-In And Absentee Ballots Explained.

ELIfast has been validated and approved by ICMR and the National Institute of Virology (NIV), Pune, it added.

IgG antibody tests identify the immune status of the individuals to COVID-19. ICMR has recommended these tests for conducting sero-surveillance, the statement said.

Shares of Cipla Ltd on Wednesday closed at Rs 765.15 per scrip on the BSE, down 0.69 per cent from its previous close.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)